Vulvodynia: What We Know and Where We Should Be Going. Issue 2 (April 2017)

• Record Type: Journal Article
• Authors: Havemann, Logan M.; Cool, David R.; Gagneux, Pascal; Markey, Michael P.; Yaklic, Jerome L.; Maxwell, Rose A.; Iyer, Ashvin; Lindheim, Steven R.
• Is Part Of: Journal of lower genital tract disease. Volume 21:Issue 2(2017:Apr.)
• Publication Date: 2017-04
• Subjects: vulvodynia -- microbiome -- genomics -- proteomics -- glycomics; Generative organs, Female -- Diseases -- Periodicals; Cervix uteri -- Diseases -- Periodicals; Generative organs -- Diseases -- Periodicals; Sexually transmitted diseases -- Periodicals; 618.1
• DOI: 10.1097/LGT.0000000000000289
• Languages: English
• ISSNs: 1089-2591

Abstract

Abstract : Objective: The aim of the study was to review the current nomenclature and literature examining microbiome cytokine, genomic, proteomic, and glycomic molecular biomarkers in identifying markers related to the understanding of the pathophysiology and diagnosis of vulvodynia (VVD). Materials and Methods: Computerized searches of MEDLINE and PubMed were conducted focused on terminology, classification, and "omics" variations of VVD. Specific MESH terms used were VVD, vestibulodynia, metagenomics, vaginal fungi, cytokines, gene, protein, inflammation, glycomic, proteomic, secretomic, and genomic from 2001 to 2016. Using combined VVD and vestibulodynia MESH terms, 7 references were identified related to vaginal fungi, 15 to cytokines, 18 to gene, 43 to protein, 38 to inflammation, and 2 to genomic. References from identified publications were manually searched and cross-referenced to identify additional relevant articles. A narrative synthesis of the articles was conducted; however, meta-analysis was not conducted because of substantial heterogeneity in the studies and limited numbers of control-matched studies. Results: Varying definitions of VVD complicate a meta-analysis, and standard definitions will better allow for comparisons of studies and enhance the applicability of evidence to patient populations. Although data are still limited, genomic and molecular diagnostic testings continue to be investigated as potential tools for the diagnosis of VVD. Conclusions: Standardized nomenclature will allow for comparability of studies and progress in research related to the pathophysiology of VVD and to facilitate clinical decision making and treatment choices. Although the current understanding of the pathogenesis of VVD is limited, there are new opportunities to explore potential diagnostic markers differences in women with VVD, which may lead to targeted therapy. Abstract : Vulvodynia terminology and potential cytokine, genomic, proteomic, and glycomic diagnostic markers were reviewed.